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ABSTRACT 
Background    Vitamin B12 is stored primarily in the 
liver, and highly elevated serum vitamin B12 levels occur 
in acute hepatitis and severe alcoholic liver disease. We 
evaluated the relationship between vitamin B12 levels 
and liver disease severity and long term prognosis in pa-
tients with chronic viral hepatitis and cirrhosis. 
Methods    We enrolled 90 patients (57 men, 33 women) 
with chronic viral hepatitis and cirrhosis who admitted 
to our hospital as a prospective cohort study. Overall, 
37 patients had chronic hepatitis and 53 had cirrhosis 
(Child-Pugh A 33, B 13, and C 7); 57 patients had pri-
mary liver cancer. Serum vitamin B12 concentration and 
holotranscobalamin (holoTC) II (active form of vitamin 
B12) were determined and followed prospectively for at 
least 5 years.
Results    Mean total serum vitamin B12 concentration 
was significantly higher in Child-Pugh C (1308 ± 599 
pg/mL) compared to those with chronic hepatitis (655 
± 551 pg/mL), Child-Pugh A (784 ± 559 pg/mL), and 
Child-Pugh B (660 ± 464 pg/mL) (P = 0.036) Presence 
of primary liver cancer also influenced serum vitamin 
B12 levels [657 (167–2956) vs. 432 (189–2956); P = 0.015]. 
Patients were divided into quartiles by vitamin B12 level. 
Patients without primary liver cancer in quartile 4 (≥ 
880 pg/mL) demonstrated significantly poorer prognosis 
than those in quartiles 1–3 (< 880 pg/mL) (P = 0.023). 
The percentage of holohaptocorrin (holoHC) [(total vita-
min B12 – holoTC II) × 100] was significantly higher in 
Child-Pugh B and C 86 (80–87)% than chronic hepatitis 
and Child-Pugh A 77 (31–89)% (P = 0.006) Multivariate 
analysis indicated serum vitamin B12 levels (HR = 1.001, 
P = 0.029) as a prognostic factor.
Conclusion    Falsely elevated serum vitamin B12 levels 
mainly composed of increased holoHC were associated 
with severity (Child-Pugh C and primary liver cancer) 
and prognosis in chronic viral liver disease.
Key words    holotranscobalamin; liver cirrhosis; prog-
nosis; viral hepatitis; vitamin B12
Vitamin B12 is stored primarily in the liver; this vitamin 
is essential for one-carbon metabolism and cell divi-
sion. It acts as a cofactor for two enzymatic reactions, 
namely, methionine synthesis from homocysteine and 
succinyl-CoA synthesis from methylmalonyl-CoA, in 
mammalian systems.1 Some studies have indicated that 
elevated serum levels of vitamin B12 might be a sign of 
a serious and life-threatening disease. Such falsely high 
valued of serum vitamin B12 levels are observed in my-
eloproliferative disease, acute hepatitis, severe alcoholic 
liver disease, and cirrhosis.2–6
 Vitamin B12 binds with transcobalamin (TC) II. The 
complex holoTC II, which is the biologically active form 
of vitamin B12, is recognized by specific receptors on 
all cell types. The active form of vitamin B12 comprises 
only 6–20% of the total serum vitamin B12 level. The re-
maining major portion (70–90%) is bound to haptocor-
rin (HC); this is named holohaptocorrin (holoHC) and 
is the inactive form of vitamin B12, which is stored in 
the liver.7, 8 Several reports have reported that the falsely 
high values are due to increasing the holoHC levels.3
 In our experience, we have observed highly elevated 
vitamin B12 levels in patients with advanced stages of vi-
ral liver cirrhosis. There are only one report that demon-
strated the association of vitamin B12 level with disease 
severity and mortality in hepatitis B virus infection with 
short term.9 No reports have evaluated the dynamics of 
vitamin B12 in chronic viral hepatitis. Accordingly, the 
present study aimed to evaluate the relationship of serum 
vitamin B12 between the disease severity and long term 
prognosis of liver disease in patients with viral hepatitis 
and cirrhosis.
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SUBJECTS AND METHODS
Subjects
From March 2007 to March 2010, consecutive patients 
with chronic viral hepatitis and viral induced cirrhosis 
were prospectively enrolled in the present study. Patients 
who underwent a total gastrectomy, vegetarians and 
those receiving nutrient supplementation, including vita-
min B12, were excluded from the study. 
Methods
Cirrhosis was diagnosed according to clinical, biochem-
ical, and/or imaging findings. The severity of cirrhosis 
was categorized using the Child-Pugh classification.10 
The presence of primary liver cancer was also recorded. 
The stages of hepatocellular carcinoma (HCC) were cat-
egorized by TNM staging. Blood samples were collected 
at the date of inclusion, and hemoglobin, blood chemis-
try [albumin, total bilirubin, aspartate aminotransferase 
(AST), alanine aminotransferase (ALT)], prothrombin 
activity percentage, alpha-fetoprotein (AFP), and des-γ-
carboxy prothrombin (DCP), and serum vitamin B12 lev-
els were determined. Total serum vitamin B12 concentra-
tion was determined by chemiluminescent immunoassay 
(CLIA: Access Vitamin B12; beckman coulter, Tokyo, 
Japan). Levels of holoTC II were also measured by mi-
croparticle enzyme immunoassay (AxSYM Active-B12; 
abbott diagnostics, Abbott Park, IL). The percentage of 
holoTC II was expressed as the ratio of holoTC II to total 
serum vitamin B12. The percentage of holoHC was cal-
culated as (total vitamin B12 – holoTC II) × 100. All the 
patients were followed prospectively for at least 5 years 
and evaluated for prognosis. 
Ethical Considerations
The study protocol confirmed to the ethical guidelines 
of the Helsinki Declaration of 1975, as revised in 2000, 
and was approved by the ethics committee of the Tottori 
University (No. 1231). Patients were enrolled after giv-
ing their written informed consent.
Statistical analysis
Data are expressed as median (range) or mean ± SD. 
Statistical analyses for significant differences among 
the groups were performed using the chi-square test, 
Student’s t test, Mann-Whitney’s U test, ANOVA, and 
Kruskal-Wallis Test. F test and Bartlett’s test was used 
to assess the equality of variances. Correlations were 
calculated using Pearson’s product-moment correlation 
coefficient. Cumulative survival rate was calculated by 
the Kaplan-Meier method, and significant differences 
between two groups were calculated using the Log rank 
test. Multivariate analyses were performed using the 
Cox proportional hazards model. Statistical significance 
was set at P < 0.05.
RESULTS
Patient background
Ninety patients [57 men, 33 women; median age, 69 
(range, 30–88) years] were enrolled this study. Of these 
patients, 60 (67%) had hepatitis C virus (HCV) and 30 
patients (33%) had hepatitis B virus (HBV). Twenty 
patients (22%) habitually consumed ≥ 20 g/day alcohol. 
Seven patients (8%) had heart disease (e.g. ischemic 
heart disease, valvular heart disease, and arrhythmia). 
Nine patients (10%) underwent distal gastrectomy. Un-
derlying liver disease was chronic hepatitis in 37 patients 
(41%) and cirrhosis in 53 (59%) (Table 1). 
Table 1. Clinical findings in study subjects 
Patients n = 90
Sex (Male:Female) 57:33
Age (years) 69 (30–88) 
Etiology
HBV infection 30 (33%)
HCV infection 60 (67%)
Alcohol consumption (≥ 20 g/day) 20 (22%)
Comorbidity
Heart disease 7 (8%)
Gastrectomy (distal) 9 (10%)
Atrophic gastritis 33 (37%)
The severity of underlying liver disease
Chronic hepatitis 37 (41%)
Cirrhosis 53 (59%)
Child-Pugh classification
(A:B:C) 33:13:7
Primary Liver Cancer (HCC:ICC) 56:1 (62%)
TNM Stage  
( I:II:II:IVA:IVB:unknown) 18:11:17:4:5:2
Laboratory values
Hemoglobin (g/dL) 12.3 (6.5–16.9)
MCV (fL) 95.8 (62.4–112.9)
MCHC (%) 34.4 (31.4–36)  
Albumin (g/dL) 3.6 (2.1–5.1) 
AST (IU/L) 47 (14–847) 
ALT (IU/L) 37 (7–1073) 
Total bililubin (mg/mL) 0.8 (0.3–15.1)
Prothrombin percent activity   (%) 86.9 (5–117.1) 
Total serum vitamin B12 (pg/mL) 584.5 (160–2956)
AFP (ng/mL) 8.7 (1.2–501570)
DCP (mAU/mL) 24 (10–84980)
Data are expressed as median (range).
AST, aspartate aminotransferase; ALT, alanine aminotransferase; 
AFP, alpha fetoprotein; DCP, Des-gamma-carboxy prothrombin; 
HBV, hepatitis B virus; HCV, hepatitis C virus; HCC, hepatocel-
lular carcinoma; ICC, intrahepatic cholangiocellular carcinoma; 
MCV, mean corpuscular volume; MCHC, mean corpuscular he-
moglobin concentration; TNM, TNM classification of malignant 
tumours. 
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Vitamin B12 analysis
Serum vitamin B12 levels were significantly higher 
in patients with cirrhosis than chronic hepatitis [647 
(160–2956) vs. 461 (189–2956) pg/mL (P = 0.029)], and 
it was particularly in patients categorized as Child-Pugh 
C (1308 ± 599 pg/mL) than those with chronic hepatitis 
(655 ± 551pg/mL), Child-Pugh A (784 ± 559 pg/mL), 
and Child-Pugh B (660 ± 464 pg/mL) (P = 0.036) (Fig.1). 
The vitamin B12 levels were also higher in patients with 
primary liver cancer than those without [657 (167–2956) 
vs. 432 (189–2956) pg/mL, P = 0.015] (Table 2). 
 Then we divided the patients with and without pri-
mary liver cancer. Among the patients with primary 
liver cancer, the vitamin B12 levels were found to be 
significantly higher in drinkers (alcohol consumption 
≥ 20 g/day) than non-drinkers [885 (160–2956) vs. 625 
(263–2265) pg/mL, P = 0.025]. On the other hand, 
among the patients without primary liver cancer, it was 
significantly higher in patients with hepatitis B virus in-
fection than hepatitis C virus infection [655 (272–2956) 
vs. 392 (189–1083) pg/mL, P = 0.018], and the patients 
with cirrhosis than chronic hepatitis [655 (379–2956) vs. 
386 (189–1200) pg/mL, P = 0.004] (Table 3).
 Moreover, we also divided the patients with chronic 
hepatitis and cirrhosis to separate the influence of liver 
function on vitamin B12 for each parameter. Vitamin B12 
levels were significantly higher in primary liver cancer 
only in patients with chronic hepatitis [731 (196–2956) 
vs. 386 (189–1200) pg/mL, P = 0.009] (Table 4).
 To evaluate the relationship of serum vitamin B12 
with the patients’ clinical and biochemical parameters, 
the correlations between serum vitamin B12 levels and 
those parameters (age, hemoglobin, mean corpuscular 
volume, mean corpuscular hemoglobin concentration, 
albumin, AST, ALT, total bilirubin, prothrombin activ-
ity percentage, AFP, and DCP) were estimated using 
Pearson’s product-moment correlation coefficient. Serum 
vitamin B12 levels were positively correlated with AFP (r 
= 0.231, P = 0.04), negatively prothrombin activity per-
centage (r = –0.248, P = 0.017) (Table 5). 
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Fig. 1. Serum vitamin B12 levels in patients with chronic viral 
hepatitis. Serum vitamin B12 levels were significantly higher in 
patients categorized as Child-Pugh C (1308 ± 599 pg/mL) than 
those in CH (655 ± 551 pg/mL), Child-Pugh A (784 ± 559 pg/mL), 
and Child-Pugh B (660 ± 464 pg/mL) (P = 0.036). *P < 0.05. CH, 
chronic hepatitis. 
Table 2. Influence of clinical factors on serum vitamin B12 levels
Serum vitamin B12 (pg/mL)
All patients (n = 90) P value
Sex (Male:Female) 581 (196–2956):640 (160–2956) n.s.
Etiology (HCV:HBV) 513 (189–2956):656 (160–2956) n.s.
Alcohol ≥ 20g/day (Yes:No) 660 (160–2956):520 (263–2265) n.s.
Heart disease (Yes:No) 431 (320–1298):410 (160–2956) n.s.
Gastrectomy* (Yes:No) 607 (160–2956):367 (263–1494) n.s.
Cirrhosis (Yes:No) 647 (160–2956):461 (189–2956) 0.029
Primary liver cancer (Yes:No) 657 (160–2956):432 (189–2956) 0.015
TNM Stage (I/II:III/IVA/IVB) 549 (233–2956):728 (160–2265) n.s.
Data are expressed as median (range). *Distal gastrectomy.
HBV, hepatitis B virus; HCV, hepatitis C virus; TNM, TNM classification of malignant tumours; n.s., not significant. 
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Table 3. Influence of clinical factors on serum vitamin B12 levels between patients with and without primary liver 
cancer
Serum vitamin B12 (pg/mL)
Patients with primary liver cancer 
(n = 57) P value
Patients without 
primary liver cancer (n = 33) P value
Sex 632 (196–2956):686 (160–1957) n.s. 461 (277–1200):410 (189–2956) n.s.
(Male:Female)
Etiology 664 (205–2956):657 (160–2029) n.s. 392 (189–1083):655 (272–2956) 0.018
(HCV:HBV)
Alcohol ≥ 20 g/day 885 (160–2956):625 (263–2265) 0.025 432 (299–1083):410 (189–2956) n.s.
(Yes:No)
Heart disease 819 (160–2956):647 (320–1298) n.s. 581 (581–581):424 (189–2956) n.s.
(Yes:No)
Gastrectomy* 320 (263–1494):686 (160–2956) n.s. 283 (367–379):461 (189–2956) n.s.
(Yes:No)
Cirrhosis 645 (160–2265):731 (196–2956) n.s. 655 (379–2956):386 (189–1200) 0.004
(Yes:No)
TNM Stage 549 (233–2956):728 (160–2265) n.s. — —
( I/II:III/IVA/IVB)
Data are expressed as median (range). *Distal gastrectomy.
HBV, hepatitis B virus; HCV, hepatitis C virus; TNM, TNM classification of malignant tumours; n.s., not significant. 
Table 4. Influence of clinical factors on serum vitamin B12 levels between patients with chronic hepatitis and  
cirrhosis
Serum vitamin B12 (pg/mL)
Patients with chronic hepatitis (n = 37) P value Patients with cirrhosis (n = 53) P value
Sex 509 (196–2956):189 (189–1298) n.s. 631 (205–2265):647 (160–2956) n.s.
(Male:Female)
Etiology 432 (189–2956):634 (196–1298) n.s. 640 (205–2265):656 (160–2956) n.s.
(HCV:HBV)
Alcohol ≥ 20 g/day 461 (299–1298):449 (189–2956) n.s. 1083 (263–2265):624 (160–2956) n.s.
(Yes:No)
Heart disease 634 (320–1298):432 (189–2956) n.s. 952 (367–1292):645 (160–2956) n.s.
(Yes:No)
Gastrectomy* 344 (320–367):483 (189–2956) n.s. 263 (160–2956):379 (263–1494) n.s.
(Yes:No)
Primary liver cancer 731 (196–2956):386 (189–1200) 0.009 645 (160–2265):655 (379–2956) n.s.
(Yes:No)
TNM Stage 526 (233–2956):731 (196–1417) n.s. 751 (263–1957):472 (160–2965) n.s.
( I/II:III/IVA/IVB)
Data are expressed as median (range). *Distal gastrectomy.
HBV, hepatitis B virus; HCV, hepatitis C virus; TNM, TNM classification of malignant tumours; n.s., not significant. 
HoloTC II analysis
In 43 of 90 patients, levels of holoTC II were evaluated. 
We found that the percentage of holoTC II tended to 
decrease with progression of liver disease. The median 
percentages of holoTC II were 22(11–69)% in patients 
with chronic hepatitis (n = 25), 24 (19–37) % in Child-
Pugh A (n = 13), 16 (13–20)% in Child-Pugh B (n = 
4), and 13% in Child-Pugh C (n = 1), and the statistical 
significance was indicated between Child-Pugh A and 
B (P = 0.031) (Fig. 2A). The percentage of holoHC was 
significantly higher in Child-Pugh B and C 86 (80–87)% 
compared with chronic hepatitis and Child-Pugh A 77 
(31–89)% (P = 0.006) (Fig. 2B). 
Survival analysis
During the observation period (median, 54.3 months; 
range, 0.6–101.7months), the overall survival rates were 
89% at 1 year, 81% at 2 years, and 67% at 5 years. Cir-
rhotic patients had significantly poorer prognosis com-
pared with non-cirrhotic patients [33.5 (0.6–101.7) vs. 
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Table 5. Correlations between serum vitamin B12  
levels and clinical/biochemical parameters
Patients (n = 90) r P value
Sex –0.038 n.s.
Age (year) –0.005 n.s.
Hemoglobin (g/dL) –0.053 n.s
MCV (fL) –0.018 n.s
MCHC (%) 0.001 n.s
Albumin (g/dL) –0.203 n.s.
AST (IU/L) 0.168 n.s.
ALT (IU/L) 0.114 n.s.
Total bilirubin (mg/mL) 0.113 n.s.
Prothrombin percent activity –0.248 0.017
AFP 0.231 0.040
DCP 0.084 n.s.
AFP, alpha-fetoprotein; AST, aspartate aminotransferase; ALT, 
alanine aminotransferase; BTR, branched-chain amino acids to 
tyrosine ratio; DCP, des-γ-carboxy prothrombin; MCV, mean cor-
puscular volume; MCHC, mean corpuscular hemoglobin concen-
tration; n.s., not significant.
66.9 (3.1–72.1) months, P = 0.003]. Patients with prima-
ry liver cancer had also significantly poorer prognosis 
compared to those without them [28.5 (0.6–101.7) vs. 
67 (15.6–71.7) months, P < 0.001]. Ninety patients were 
divided into quartiles Q1 to Q4, according to serum 
vitamin B12 level: Q1, < 403.25; Q2, 403.25–582; Q3, 
583–879; and Q4, ≥ 880 pg/mL (Fig. 3A). Among all 
the patients, Q4 had markedly low cumulative survival 
Fig. 2. Percentage of holoTC II and holoHC.
A: Percentage of holoTC II was significantly different between Chid-Pugh A and B (P = 0.031). *P < 0.05. B: The percentage of holoHC 
[(total vitamin B12 – holoTC II) × 100] was significantly higher in Child-Pugh B and C 86 (80–87)% than chronic hepatitis (CH) and 
Child-Pugh A 77 (31–89)% (P = 0.006). **P < 0.01. holoHC, holohaptocorrin; holoTC, holotranscobalamin.
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rate than those Q 1-3 (P = 0.058) (Fig. 3B). On the other 
hand, among the patients without primary liver cancer, 
Q4 had significantly low cumulative survival rate than 
Q 1-3 (P = 0.003) (Fig. 3C). Univariate analysis revealed 
that serum albumin, total bilirubin, AFP > 10 ng/mL, 
DCP > 40 AU/mL, and serum vitamin B12 level were 
significant prognostic factors for the overall survival 
rate. The stepwise multivariate Cox proportional hazards 
model showed that the independent factors contributing 
to cumulative survival rate were serum albumin, DCP > 
40 AU/mL and serum vitamin B12 levels (Table 6). 
DISCUSSION
Our study demonstrated two important findings. First, 
serum vitamin B12 levels were significantly elevated in 
patients categorized as Child-Pugh C and with prima-
ry liver cancer. Second, serum vitamin B12 level was a 
significant independent predictor for overall survival in 
patients with chronic viral liver disease.
 We found that serum vitamin B12 levels were sig-
nificantly higher in cirrhotic patients with Child-Pugh C 
than in patients with chronic hepatitis or Child-Pugh A/
B cirrhosis. It has been previously reported that highly 
elevated vitamin B12 levels in plasma were indicated in 
acute hepatitis, severe alcoholic liver disease, and cirrho-
sis.2–6, 11, 12 Our data indicate that serum vitamin B12 lev-
els were falsely elevated with the severity also in chronic 
viral liver disease. Total serum vitamin B12 levels were 
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Fig. 3. Cumulative survival rate calculated by the Kaplan-Meier 
method, by serum vitamin B12 level quartiles.
A: The 90 patients were divided into quartiles by vitamin B12 
level: < 403.25 (Q1, solid line); 403.25–582 (Q2, dotted line), 583–
879 (Q3, dashed line), and ≥ 880 pg/mL (Q4, dash-dotted line). 
B: Cumulative survival rate differed between Q 1-3 (solid line) 
and Q4 (dotted line) in all the patients (P = 0.058). C: Cumulative 
survival rate differed significantly between Q 1-3 (solid line) and 
Q 4 (dotted line) in the patients without primary liver cancer (P = 
0.003). 
Table 6. Univariate and multivariate analyses of factors predicting the overall survival rate
Factors UnivariateP value 
Multivariate analysis
HR 95% CI P value
Sex 0.374
Age year 0.369
Albumin g/dL < 0.001 0.368 0.176–0.767 0.008
Total bilirubin mg/dL 0.006 1.231 0.915–1.658 0.170
PT % 0.086 1.010 0.984–1.036 0.457
AFP > 10 ng/mL 0.003 1.546 0.632–3.781 0.340
DCP > 40 AU/mL < 0.001 2.682 1.084–6.636 0.033
Serum vitamin B12 pg/mL 0.034 1.001 1.000–1.001 0.029
CH,chronic hepatitis; AFP, alpha fetoprotein; CI, confidence interval; DCP, des-γ-carboxy prothrombin; HR, hazard 
ratio; PT, prothrombin percent activity.
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significantly higher in cirrhotic patients. The biomarker 
of hepatic reserve, such as prothrombin activity percent-
age, was found to be weakly correlated with the total 
serum vitamin B12 levels in the present study.
 Among the patients with primary liver cancer, the 
vitamin B12 level was higher in alcohol consumption ≥ 
20 g/day group than in those were not. Alcoholic liver 
disease have already shown to have the falsely high 
vitamin B12 levels associated with liver dysfunction.4, 5 
On the other hand, among the patients without primary 
liver cancer, serum vitamin B12 levels were significantly 
higher in HBV than those in HCV patients. The reason 
was the number of patients classified into Child-Pugh B 
and C was significantly higher in HBV patients without 
primary liver cancer (data not shown). 
 Total serum vitamin B12 levels were also signifi-
cantly higher in patients with primary liver cancer than 
those without. Some reports have also indicated that 
serum vitamin B12 levels are elevated in patients with 
HCC.13–15 However, primary liver cancer is usually com-
plicated with viral cirrhosis, the elevation should be dis-
tinguished from the association with cirrhosis. In present 
study, the difference was demonstrated only in patients 
with chronic hepatitis. Therefore, it could be concluded 
that primary liver cancer directly associated with serum 
vitamin B12 levels. 
 According to these findings, we could demonstrate 
that severe liver dysfunction (Child-Pugh C) and prima-
ry liver cancer affected the falsely elevated vitamin B12 
levels.
 In this study, we analyzed holoTC II additionally in 
some patients to clarify the mechanisms of falsely eleva-
tion. Unfortunately, we could evaluate only one patient 
in Child-Pugh C. We observed significantly lower level 
(within normal range) of the holoTC II percentage in pa-
tients of Child-Pugh B and C. It also means the percent-
age of holoHC increased in Child-Pugh B and C. 
 Thus, we propose two mechanisms responsible for 
elevated serum vitamin B12 levels in these patients (Fig. 
4). First, holoHC possibly leaks into the circulation due 
to the destruction of hepatocytes (excess release hypoth-
esis). This is supported by the observation that plasma 
vitamin B12 levels are elevated in 25–40% cases of acute 
hepatitis.2, 11, 16, 17 However, in our study, serum vitamin 
B12 levels did not correlate with transaminase levels, this 
hypothesis could not explain high serum vitamin B12 in 
chronic viral hepatitis. Alternatively, the reduced uptake 
of holoHC by the injured liver may contribute to elevated 
levels of serum vitamin B12 (reduced clearance hypoth-
esis). The asialoglycoprotein receptors, which bind ho-
loHC for uptake into the liver, are expressed on normal 
hepatocytes. Since the number of receptors decreases 
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  Liver　	
　　Liver	  cancer	　　　Cirrhosis	
Circula2on	
×	×	
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  the	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  of	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Fig.4 Fig. 4. Scheme of the hypothesis for falsely elevated vitamin B12 in liver disease.
HoloHC (■), the inactive form of vitamin B12, is stored in the liver. The stored holoHC adjusts holoTC II(▲), the inactive form of vitamin 
B12, in circulation. There are possible two mechanisms responsible for falsely elevated serum vitamin B12 levels in liver diseases. First, 
holoHC leaks into the circulation due to the destruction of hepatocytes (excess release hypothesis). Second, the reduced uptake of holoHC 
by the injured liver (reduced clearance hypothesis). holoHC, holohaptocorrin; holoTC, holotranscobalamin.
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with the destruction of hepatocytes or the progression of 
liver cancer, holoHC remains in the circulation.14, 15 The 
study using liver biopsy specimens have shown that the 
loss of vitamin B12 storage in the liver is associated with 
increased serum vitamin B12 levels.16, 18–21
 In our study, elevated levels of serum vitamin B12 
were also associated with poor prognosis. Some reports 
have already indicated that vitamin B12 levels are asso-
ciated with increased mortality in critically ill patients 
of other diseases.22, 23 The mechanisms that affect the 
prognosis of such patients remain unknown; however, 
based on the known aspects of hepatic inflammation and 
oxidative stress, it is possible to speculate on the mech-
anism. Previous reports have also shown that vitamin 
B12 modulates inflammation. The relationship between 
vitamin B12 and cytokine levels was demonstrated in hu-
mans.24 In the report, vitamin B12 deficiency was related 
to high levels of tumor necrosis factor-alpha (TNF-α), 
and vitamin B12 supplementation normalized these lev-
els. TNF-α is a well-known cytokine that plays a crucial 
role in chronic inflammation as well as in chronic hep-
atitis.25, 26 Another report has indicated that vitamin B12 
may regulate nuclear factor kappa B (NFκB), which is 
transcription regulator activated by cytokines like TNF-α, 
and it determines cell survival and apoptosis.27, 28 These 
reports suggest that vitamin B12 plays the role of a modu-
lator for cytokine expression in the injured liver where 
the vitamin B12 storage has diminished. 
 Tamura et al. also indicated the role of vitamin B12 
as an immunomodulator.29 demonstrating that vitamin 
B12 administration increased the percentages of cluster 
of differentiation (CD) 8+ cells and natural killer (NK) 
cells in vitamin B12-deficient patients. Moreover, Birch et 
al. reported thiolatocobalamin (a vitamin B12 derivative) 
has a protective effect on oxidant-damaged cells.30 Fur-
thermore, the hepatoprotective effect of vitamin B12 has 
been demonstrated using dimethylnitrosamine-induced 
liver injury in a mouse model.31 This hepatoprotective 
effect of vitamin B12 may be achieved by the mainte-
nance of sulfhydryl levels under oxidative conditions. 
 Taken all things together, the association of falsely 
elevated vitamin B12 with prognosis is considered to be 
due to diminished hepatic storage (excess release or re-
duced clearance) and loss of its hepatoprotective effect.
 However, it remains unclear whether the hepatic 
vitamin B12 storage has any effect on maintain hepatic 
function in normal liver. The efficacy of vitamin B12 
supplementation for cirrhosis also remains unknown. 
Further studies are needed to clarify the role of vitamin 
B12 in hepatic diseases.
 A limitation of our study is the small number of pa-
tients. The prognosis of Q4 (vitamin B12 ≥ 880 pg/mL) 
was significantly poor only in the patients without pri-
mary liver cancer; however, primary liver cancer is usu-
ally complicated with cirrhosis. To predict the prognosis 
of viral liver disease, appropriate cut-off level should be 
determined in all the patients. Large-scale study should 
be conducted to clarify the cut-off level of serum vita-
min B12 for viral liver disease.
 In conclusion, falsely elevated serum vitamin B12 
levels mainly composed of its increased holoHC were 
associated with severity and prognosis in viral liver dis-
ease. 
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